Allan JN1,
Friedman KD,
DeSancho MT. Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.
Int J Hematol. 2014 Dec;100(6):602-6. doi: 10.1007/s12185-014-1662-3. Epub 2014 Sep 12.
Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K. Emerging issues in diagnosis, biology, and inhibitor risk in mild hemophilia A. In: Seminars in thrombosis and hemostasis: thieme Medical Publishers; 2016. pp. 507-512.
Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ. 2012 May 02;344:e2707.
Iorio A, Oliovecchio E, Morfini M, Mannucci P, Directors AoIHC. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008,14:444-453.
Jensson O, BERNVIL SS, JÖNSÖDTTIR S, Ingerslev J. Mild haemophilia A in Iceland: clinical genetic studies of three families with the same mutation. Journal of internal medicine 1994,235:443-450.
Konkle BA, Huston H, Nakaya Fletcher S.
Hemophilia A. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med. 2007;45:2–12.
Peters R, Harris T.
POON MC, LUKE KH. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia 2008,14:879-888.
Powell JS1. Recombinant factor VIII in the management of hemophilia A: current use and futurepromise.
Ther Clin Risk Manag. 2009 Apr;5(2):391-402. Epub 2009 May 20.
Srivastava, A. et al. Guidelines for the management of hemophilia. Haemophilia 19, e1–e47
Walker I, Pai M, Akabutu J, Ritchie DB, Growe G, Poon MC, et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995,35:548-551.